ClinicalTrials.gg
Enrolling by invitationNCT07545564Updated Apr 22, 2026

A Study on Mucosal Specific IgA Immunokinetics After Administration of Nasal Spray Live Attenuated Influenza Vaccine

A Phase 4 interventional study of LAIV and Placebo in Influenza, sponsored by Changchun BCHT Biotechnology Co.. Enrolling by invitation at 1 site in China. Open to participants aged 3 Years to 17 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-22.

Sponsored by Changchun BCHT Biotechnology Co. · Phase 4, Interventional, and Prevention

From the registry’s dates

  • Primary completion was expected by Apr 2026, 6 months ago, but the record still lists the study as enrolling by invitation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
3 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 37 studies testing FluMist in Influenza, Human — 4 open to participants now, 7 under way, none of them phase 3. FluMist · Influenza, Human.

Planned enrollment
13th of 37
200 · median 72
Started
2026
with 1 other
Phase 4
21 of 37
3 open now
Registered
36th of 37
by date
Lead sponsor
1 of 37
Changchun BCHT Biotechnology Co.

Among the 37 studies testing FluMist in Influenza, Human, this one is the 13th largest by planned enrollment, is one of 2 that started in 2026, is one of 21 in phase 4, and was the 36th registered.

Influenza, Human

2,358 studies on the registry are indexed under Influenza, Human; 184 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

4 of the 37 studies testing FluMist in Influenza, Human are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About FluMist

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 121 Influenza, Human studies recruiting now, 66 (55%) set no upper age limit and 45 (37%) stop at 75 or younger; 33 take children under 18; 67 take healthy volunteers.

This study: 3 Years to 17 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies testing FluMist in Influenza, Human, or all of them as a file.
02

Study summary

Mucosal-specific sIgA antibody GMT;Evaluate the achievement of 2-fold and 4-fold increases in the geometric mean titer (GMT) of specific nasal mucosal sIgA antibodies after vaccination

03

Conditions studied

  • Influenza

Browse trials for

04

Who can participate

Ages eligible
3 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • People aged 3 to 17 years old who voluntarily receive the live attenuated influenza nasal spray vaccine;
  • The participant themselves can comply with the protocol requirements and complete sample collection;
  • Obtain the consent of the participants' guardians and sign the form;

Exclusion criteria

Exclusion Criteria:

  • Axillary temperature > 37.0°C on the day of enrollment;
  • Received any influenza vaccine within the past 2 years and plans to receive other influenza vaccines during the trial period;
  • Clinically diagnosed with influenza in a medical institution within the past year (with confirmed etiological diagnosis);
  • Individuals with known to any ingredient contained in this product, including eggs, , and gentamicin sulfate;
  • Individuals suffering from acute diseases, severe chronic diseases, acute exacerbations of chronic diseases, and fever;
  • Pregnant women;
  • Patients with Leigh syndrome who are being treated with aspirin or aspirin-containing medications;
  • Individuals with immunodeficiency or those undergoing therapy;
  • Individuals with uncontrolled epilepsy and other progressive neurological diseases, or those with a history of Guillain-Barré syndrome;
  • Nasal abnormalities that, in the judgment of a clinician, may affect vaccination, individuals in the medication period for allergic rhinitis, or those currently receiving nasal spray administration;
  • Having received a within 14 days prior to enrollment, or a subunit or inactivated vaccine within 7 days prior to enrollment;
  • Presence of other factors deemed unsuitable for participation in this study by the investigator.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Vaccine

    LAIV

    Biological: LAIV

  • Placebo comparator
    Placebo

    sterile water

    Biological: Placebo

Interventions

  • BiologicalLAIV

    Nasal spray live attenuated influenza vaccine

  • BiologicalPlacebo

    sterile water

06

What researchers measure

Primary outcomes

  1. Membrane-specific sIgA antibody

    Time frame: 14days after vaccination

07

Study locations

1 site
  • Neimenggu CDC
    Hohhot, Inner Mongolia, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Apr 2026, 0 months after the start.

Of 37 industry-sponsored phase 4 interventional studies under Influenza, Human, half reached primary completion within 3 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 6. This study's planned 0 months is below that.

Counting every sponsor, half of 138 studies reached it within 14 months; a quarter within 3 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2026
First posted
Apr 22, 2026
StartActual
Apr 9, 2026
Primary completionEst.
Apr 23, 2026
CompletionEst.
May 9, 2026
Last update
Apr 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07545564
Lead sponsor
Changchun BCHT Biotechnology Co.
Responsible party
Sponsor
First posted
Apr 22, 2026
Start date
Apr 9, 2026
Primary completion
Apr 23, 2026 (estimated)
Completion
May 9, 2026 (estimated)
Last update
Apr 22, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: FluMist

Start the discussion